Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cdca5 peptides and vaccines including the same

An immunology, HLA-A2 technology, applied in the direction of recombinant DNA technology, medical preparations containing active ingredients, peptides, etc., can solve problems such as growth arrest of lung cancer cell lines

Inactive Publication Date: 2013-02-27
ONCOTHERAPY SCI INC
View PDF28 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, siRNA suppression of CDCA5 leads to growth arrest in lung cancer cell lines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cdca5 peptides and vaccines including the same
  • Cdca5 peptides and vaccines including the same
  • Cdca5 peptides and vaccines including the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0415] Materials and methods

[0416] cell line

[0417] HLA-A*0201 positive B-lymphoblastoid cell line T2 and African green monkey kidney cell line COS7 were purchased from ATCC.

[0418] Candidate selection for peptides derived from CDCA5

[0419] Using binding prediction software "NetMHC 3.0" (www.cbs.dtu.dk / services / NetMHC / ) (Buus et al. (Tissue Antigens., 62:378-84, 2003), Nielsen et al. (Protein Sci., 12:1007-17, 2003, Bioinformatics, 20(9):1388-97, 2004)) predicts 9- and 10-mer peptides derived from CDCA5 that bind the HLA-A*0201 molecule. These peptides were synthesized by BioSynthesis (Lewisville, Texas) according to standard solid phase synthesis and purified by reverse phase high performance liquid chromatography (HPLC). The purity (>90%) and identity of the peptides were determined by analytical HPLC and mass spectrometry, respectively. Peptides were dissolved in dimethyl sulfoxide at 20 mg / ml and stored at -80°C.

[0420] In vitro CTL induction

[04...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Isolated peptides derived from SEQ ID NO: 21 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and / or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and / or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, gastric cancer, gastric diffuse-type cancer, lung cancer, lymphoma, prostate cancer, SCLC and soft tissue tumor.

Description

technical field [0001] The present invention relates to the field of biological sciences, more specifically to the field of cancer treatment. Specifically, the present invention relates to novel peptides that are extremely useful as cancer vaccines, and drugs for treating and preventing tumors. [0002] priority [0003] This application claims the benefit of US Provisional Application 61 / 322,676, filed April 9, 2010, the entire contents of which are incorporated herein by reference for all purposes. Background technique [0004] It has been demonstrated that CD8-positive CTLs can recognize epitope peptides derived from tumor-associated antigens (TAAs) appearing on MHC class I molecules, and then kill tumor cells. Since the discovery of the first example of TAA—the melanoma antigen (MAGE) family, people have mainly used immunological methods (NPL 1, Boon T, Int JCancer 1993 May 8,54(2):177-80; NPL 2, Boon T & van der Bruggen P, J ExpMed 1996 Mar 1,183(3):725-9) have disc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C12N5/0781C12N5/0783C12N5/10C12N15/09
CPCC07K7/06C07K14/4738A61K38/00A61P35/00A61P35/02C12N5/10C12N15/09
Inventor 中村佑辅角田卓也大泽龙司吉村祥子渡边朝久
Owner ONCOTHERAPY SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com